Elucidation of the mechanism that LDL counteracts the antitumor effect of sorafenib in renal cell carcinoma
| Project/Area Number |
16K20123
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
Naito Sei 山形大学, 医学部, 助教 (00431643)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | renal cell carcinoma / sorafenib / LDL / 腎癌 / 薬物耐性 / ソラフェニブ / 癌 |
|---|
| Outline of Final Research Achievements |
Development of targeted agents including sorafenib have been improving the overall survival in metastatic renal cell carcinoma patients. However, most of the patients acquire resistant for targeted agents, and develop cancer death. We defined that LDL counteracts the antitumor effect of sorafenib. Hence we investigated the mechanism.
Adding LDL into renal cancer cell lines, Akt/mTOR pathway was activated; which leads to cell proliferation and anti-cell-death. This mechanism inhibits cell-death by sorafenib and sunitinib.
|
Report
(3 results)
Research Products
(4 results)
